GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption
This article was originally published in The Pink Sheet Daily
Executive Summary
About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.